Literature DB >> 2439511

Distinct sets of acute phase plasma proteins are stimulated by separate human hepatocyte-stimulating factors and monokines in rat hepatoma cells.

H Baumann, V Onorato, J Gauldie, G P Jahreis.   

Abstract

A subline of the rat hepatoma (H-35) cells has been identified which responds to hepatocyte-stimulating factors (HSFs) of human squamous carcinoma cells by increased synthesis of all major rat acute phase plasma proteins. The regulation occurs at the level of mRNA. Two HSFs (HSF-I and HSF-II) have been purified from conditioned medium of the squamous carcinoma cells. HSF-I is a protein with an Mr = 18,000 and pI 5.5, and HSF-II is a glycoprotein with an Mr = 34,000 and a broad, neutral to basic charge. In H-35 cells, HSF-I predominantly stimulates the synthesis of complement C3 and haptoglobin and acts synergistically with dexamethasone to stimulate alpha 1-acid glycoprotein. HSF-II stimulates cysteine protease inhibitor, alpha 1-antichymotrypsin, alpha 1-antitrypsin, fibrinogen, and hemopexin, and acts synergistically with dexamethasone to stimulate alpha 2-macroglobulin. Each HSF is between 10 and 100 times less effective in regulating proteins of the other set. Human tumor necrosis factor and interleukin-1 increase complement C3, haptoglobin, and alpha 1-acid glycoprotein, as does HSF-I, but are unable to modulate any of the other acute phase proteins. The monokines differ from HSF-I is their low activity in HepG2 cells and rat hepatocytes.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2439511

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  38 in total

Review 1.  Interleukin-6 and the acute phase response.

Authors:  P C Heinrich; J V Castell; T Andus
Journal:  Biochem J       Date:  1990-02-01       Impact factor: 3.857

2.  Acute phase proteins and infectious complications after surgery for esophageal cancer.

Authors:  T Saito; A Kuwahara; K Shimoda; T Kinoshita; K Sato; M Miyahara; M Kobayashi
Journal:  Jpn J Surg       Date:  1991-11

3.  Effects of insulin, dexamethasone and cytokines on alpha 1-acid glycoprotein gene expression in primary cultures of normal rat hepatocytes.

Authors:  B Barraud; S Balavoine; G Feldmann; B Lardeux
Journal:  Inflammation       Date:  1996-04       Impact factor: 4.092

4.  The cytokine response element of the rat alpha 1-acid glycoprotein gene is a complex of several interacting regulatory sequences.

Authors:  K A Won; H Baumann
Journal:  Mol Cell Biol       Date:  1990-08       Impact factor: 4.272

Review 5.  Leukemia inhibitory factor (LIF).

Authors:  Nicos A Nicola; Jeffrey J Babon
Journal:  Cytokine Growth Factor Rev       Date:  2015-07-04       Impact factor: 7.638

6.  Interferon beta 2/B-cell stimulatory factor type 2 shares identity with monocyte-derived hepatocyte-stimulating factor and regulates the major acute phase protein response in liver cells.

Authors:  J Gauldie; C Richards; D Harnish; P Lansdorp; H Baumann
Journal:  Proc Natl Acad Sci U S A       Date:  1987-10       Impact factor: 11.205

Review 7.  Hepatic acute phase reaction in vivo and in vitro.

Authors:  H Baumann
Journal:  In Vitro Cell Dev Biol       Date:  1989-02

8.  Hepatocyte-stimulating factor, beta 2 interferon, and interleukin-1 enhance expression of the rat alpha 1-acid glycoprotein gene via a distal upstream regulatory region.

Authors:  K R Prowse; H Baumann
Journal:  Mol Cell Biol       Date:  1988-01       Impact factor: 4.272

9.  Passive immunization against tumour necrosis factor-alpha (TNF-alpha) and IL-1 beta protects from LPS enhancing glomerular injury in nephrotoxic nephritis in rats.

Authors:  A M Karkar; Y Koshino; S J Cashman; A C Dash; J Bonnefoy; A Meager; A J Rees
Journal:  Clin Exp Immunol       Date:  1992-11       Impact factor: 4.330

10.  The human hepatoma Hep3B cell line as an experimental model in the study of the long-term regulation of acute-phase proteins by cytokines.

Authors:  M Hiron; M Daveau; P Arnaud; J Bauer; J P Lebreton
Journal:  Biochem J       Date:  1992-10-01       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.